A detailed history of Susquehanna International Group, LLP transactions in Dare Bioscience, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 34,958 shares of DARE stock, worth $157,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,958
Previous 26,327 32.78%
Holding current value
$157,311
Previous $12,000 8.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$0.28 - $0.61 $2,416 - $5,264
8,631 Added 32.78%
34,958 $11,000
Q1 2024

May 07, 2024

BUY
$0.31 - $0.57 $8,161 - $15,006
26,327 New
26,327 $12,000
Q2 2023

Aug 11, 2023

BUY
$0.91 - $1.05 $149,259 - $172,222
164,021 New
164,021 $149,000
Q4 2022

Feb 14, 2023

SELL
$0.82 - $12.6 $10,284 - $158,029
-12,542 Reduced 30.2%
28,994 $24,000
Q3 2022

Nov 14, 2022

BUY
$1.04 - $12.48 $32,378 - $388,539
31,133 Added 299.27%
41,536 $42,000
Q2 2022

Aug 15, 2022

BUY
$0.94 - $1.76 $9,778 - $18,309
10,403 New
10,403 $13,000
Q2 2020

Aug 14, 2020

SELL
$0.84 - $1.11 $17,225 - $22,762
-20,507 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$0.79 - $1.7 $16,200 - $34,861
20,507 New
20,507 $17,000
Q4 2019

Feb 14, 2020

SELL
$0.72 - $0.9 $7,827 - $9,783
-10,871 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$0.74 - $0.87 $23,605 - $27,752
-31,899 Reduced 74.58%
10,871 $8,000
Q2 2019

Aug 14, 2019

BUY
$0.79 - $1.66 $25,201 - $52,954
31,900 Added 293.47%
42,770 $36,000
Q1 2019

May 15, 2019

BUY
$0.73 - $2.1 $7,935 - $22,827
10,870 New
10,870 $15,000
Q4 2018

Feb 14, 2019

SELL
$0.63 - $1.12 $6,858 - $12,192
-10,886 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$0.92 - $1.43 $10,015 - $15,566
10,886 New
10,886 $11,000

Others Institutions Holding DARE

About Dare Bioscience, Inc.


  • Ticker DARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,820,896
  • Market Cap $382M
  • Description
  • Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription pr...
More about DARE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.